- Home
- RGEN vs CAI Comparison
RGEN vs CAI Comparison
Compare RGEN & CAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGEN
- CAI
- Stock Information
- Founded
- RGEN 1981
- CAI 2008
- Country
- RGEN United States
- CAI United States
- Employees
- RGEN N/A
- CAI N/A
- Industry
- RGEN Medical/Dental Instruments
- CAI Medical Specialities
- Sector
- RGEN Health Care
- CAI Health Care
- Exchange
- RGEN Nasdaq
- CAI Nasdaq
- Market Cap
- RGEN 8.0B
- CAI 8.3B
- IPO Year
- RGEN N/A
- CAI 2025
- Fundamental
- Price
- RGEN $121.74
- CAI $29.54
- Analyst Decision
- RGEN Buy
- CAI Strong Buy
- Analyst Count
- RGEN 12
- CAI 6
- Target Price
- RGEN $168.40
- CAI $32.33
- AVG Volume (30 Days)
- RGEN 759.3K
- CAI 576.7K
- Earning Date
- RGEN 07-29-2025
- CAI 01-01-0001
- Dividend Yield
- RGEN N/A
- CAI N/A
- EPS Growth
- RGEN N/A
- CAI N/A
- EPS
- RGEN N/A
- CAI N/A
- Revenue
- RGEN $650,429,000.00
- CAI $452,498,000.00
- Revenue This Year
- RGEN $14.06
- CAI N/A
- Revenue Next Year
- RGEN $14.33
- CAI N/A
- P/E Ratio
- RGEN N/A
- CAI N/A
- Revenue Growth
- RGEN 4.88
- CAI 34.67
- 52 Week Low
- RGEN $102.97
- CAI $25.40
- 52 Week High
- RGEN $182.52
- CAI $33.41
- Technical
- Relative Strength Index (RSI)
- RGEN 48.77
- CAI N/A
- Support Level
- RGEN $116.30
- CAI N/A
- Resistance Level
- RGEN $125.00
- CAI N/A
- Average True Range (ATR)
- RGEN 5.00
- CAI 0.00
- MACD
- RGEN -0.32
- CAI 0.00
- Stochastic Oscillator
- RGEN 44.03
- CAI 0.00
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
About CAI Caris Life Sciences Inc. Common Stock
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.